Results 41 to 50 of about 1,182,206 (391)
Deoxyguanosine is a TLR7 agonist [PDF]
European Journal of Immunology, 2019 AbstractToll‐like receptor 7 (TLR7) is an innate immune sensor for single‐strand RNA (ssRNA). Recent structural analysis revealed that TLR7 has an additional binding site for nucleosides such as guanosine, and is activated when both guanosine and ssRNA bind.
Jan Rehwinkel +4 more
openaire +2 more sources
The mechanics of agonistic muscles [PDF]
Journal of Biomechanics, 2018 In this study, we tested two assumptions that have been made in experimental studies on muscle mechanics: (i) that the torque-angle properties are similar among agonistic muscles crossing a joint, and (ii) that the sum of the torque capacity of individual muscles adds up to the torque capacity of the agonist group.
Heiliane de Brito Fontana +4 more
openaire +3 more sources
BiomedicinesNamodenoson (CF102) is a small, orally available, anti-inflammatory, and anti-cancer drug candidate currently in phase 2B trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH; formerly known as non-alcoholic steatohepatitis ...
Ohad Etzion +3 more
doaj +1 more source
RIG-I agonist SLR10 promotes macrophage M1 polarization during influenza virus infection
Frontiers in Immunology, 2023 RationaleA family of short synthetic, triphosphorylated stem-loop RNAs (SLRs) have been designed to activate the retinoic-acid-inducible gene I (RIG-I) pathway and induce a potent interferon (IFN) response, which may have therapeutic potential.
Wenxin Wu +8 more
doaj +1 more source
, 2014 Dynamics and functions of G-protein coupled receptors (GPCRs) are accurately regulated by the type of ligands that bind to the orthosteric or allosteric binding sites.
Choi, Sun, Hyeon, Changbong, Lee, Yoonji
core +3 more sources
Targeting GLP-1 receptor trafficking to improve agonist efficacy
Nature Communications, 2018 Glucagon-like peptide-1 receptor (GLP-1R) activation promotes insulin secretion from pancreatic beta cells, causes weight loss, and is an important pharmacological target in type 2 diabetes (T2D).
B. Jones +20 more
semanticscholar +1 more source
Frontiers in EndocrinologyIntroductionIrritable bowel syndrome (IBS) is a severe gastrointestinal condition with symptoms like pain, bloating, diarrhea, and constipation. Glucagon-like peptide-1 (GLP-1) receptors, expressed in the central nervous system and peripheral tissues ...
Mohamed E. A. Mostafa, Tariq Alrasheed
doaj +1 more source
Potential Adiponectin Receptor Response Modifier Therapeutics
Frontiers in Endocrinology, 2019 Many human diseases may benefit from adiponectin replacement therapy, but due to pharmacological disadvantages of the intact protein, druggable options focus on peptidic, and small molecule agonists of the adiponectin receptor.
Laszlo Otvos, Laszlo Otvos, Laszlo Otvos
doaj +1 more source
Frontiers in Immunology, 2023 IntroductionTumor Associated Macrophages (TAM) are a major component of the tumor environment and their accumulation often correlates with poor prognosis by contributing to local inflammation, inhibition of anti-tumor immune response and resistance to ...
Margot Lavy +16 more
doaj +1 more source
The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs [PDF]
, 2013 G protein coupled receptors (GPCRs) are the most historically successful therapeutic targets. Despite this success there are many important aspects of GPCR pharmacology and function that have yet to be exploited to their full therapeutic potential.
Hudson, Brian D. +2 more
core +1 more source